AGM
KYMR icon

Alpine Global Management’s Kymera Therapeutics KYMR Stock Holding History

Alpine Global Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,144
Closed -$298K – 331
2021
Q2 		$298K Buy
+6,144
New +$267K 0.04% 183

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Alpine Global Management's KYMR Position: Q3 2021 in Review

Alpine Global Management sold out of Kymera Therapeutics (KYMR) in Q3 2021, closing a stake of 6,144 shares — an estimated $298K sold.

Alpine Global Management first reported a position in KYMR in Q2 2021 and held it in 1 quarter. The position peaked at $298K in Q2 2021. 115 funds tracked by Wall St. Rank hold KYMR as of Q3 2021.

  • Alpine Global Management reported no remaining Kymera Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Alpine Global Management sold 6,144 Kymera Therapeutics shares in Q3 2021, an estimated $298K.
  • Alpine Global Management first reported a position in Kymera Therapeutics in Q2 2021 and held it in 1 quarter.
  • Alpine Global Management's Kymera Therapeutics position peaked at $298K in Q2 2021.
  • 115 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2021.

Based on Alpine Global Management's 13F filing for Q3 2021, filed 12 Nov 2021.